<rdf:RDF xmlns:community="http://www.bibsonomy.org/ontologies/2008/05/community#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:admin="http://webns.net/mvcb/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:cc="http://web.resource.org/cc/" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:swrc="http://swrc.ontoware.org/ontology#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xml:base="http://www.bibsonomy.org/user/avivagabriel/cardiology"><owl:Ontology rdf:about=""><rdfs:comment>BibSonomy publications for /user/avivagabriel/cardiology</rdfs:comment><owl:imports rdf:resource="http://swrc.ontoware.org/ontology/portal"/></owl:Ontology><rdf:Description rdf:about="http://www.bibsonomy.org/bibtex/2e8968a91d51ef0df04dcd63bb2c67e79/avivagabriel"><owl:sameAs rdf:resource="http://www.bibsonomy.org/uri/bibtex/2e8968a91d51ef0df04dcd63bb2c67e79/avivagabriel"/><rdf:type rdf:resource="http://swrc.ontoware.org/ontology#Article"/><owl:sameAs rdf:resource="http://www.ingentaconnect.com/content/ben/cmc/2005/00000012/00000025/art00007"/><swrc:date>Wed Aug 08 01:50:26 CEST 2007</swrc:date><swrc:journal>Current Medicinal Chemistry</swrc:journal><swrc:month>December </swrc:month><swrc:pages>2979-2994(16)</swrc:pages><swrc:title>MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38alpha Protein</swrc:title><swrc:volume>12</swrc:volume><swrc:year>2005</swrc:year><swrc:keywords>TNF-alpha immunology kinase rheumatology p38-MAPK cardiology hematology medicine research IL-1-beta mitogen-activated inflammatory antiinflammatory inflammation proteins inhibitors p38 MAPK oncology </swrc:keywords><swrc:abstract>Mitogen-activated protein kinase p38 is a serine/threonine kinase originally isolated from lipopolysaccharide (LPS) stimulated monocytes. There are four isoforms p38agr inhibitors as potential treatment for inflammatory diseases. Herein we provide a brief overview of recent reported clinical results for AMG 548, BIRB 796, VX 702, SCIO 469, and SCIO 323. However, our focus will be on the binding modes of these inhibitors and other p38 inhibitors in the recent literature.</swrc:abstract><swrc:hasExtraField><swrc:Field swrc:value="doi:10.2174/092986705774462914" swrc:key="doi"/></swrc:hasExtraField><swrc:author><rdf:Seq><rdf:_1><swrc:Person swrc:name="Matthew R. Lee"/></rdf:_1><rdf:_2><swrc:Person swrc:name="Celia Dominguez"/></rdf:_2></rdf:Seq></swrc:author></rdf:Description></rdf:RDF>